Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care
Authors:
- Andrea VingianiAVAndrea Vingiani
- Luca AgnelliLuca Agnelli
- Matteo DucaMDMatteo Duca
- Daniele LorenziniDLDaniele Lorenzini
- Silvia DamianSDSilvia Damian
- Monica NigerMNMonica Niger
- Federico NichettiFNFederico Nichetti
- Elena TamboriniETElena Tamborini
- Alberta PiccoloAPAlberta Piccolo
- Siranoush ManoukianSMSiranoush Manoukian
Open Access
- 1 July 2023
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 7 (7) , e2300067
Abstract
PURPOSE: The investigation of multiple molecular targets with next-generation sequencing (NGS) has entered clinical practice in oncology, yielding to a paradigm shift from the histology-centric approach to the mutational model for personalized treatment. Accordingly, most of the drugs recently approved in oncology are coupled to specific biomarkers. One potential tool for implementing the mutational model of precision oncology in daily practice is represented by the Molecular Tumor Board (MTB), a multidisciplinary team whereby molecular pathologists, biologists, bioinformaticians, geneticists, medical oncologists, and pharmacists cooperate to generate, interpret, and match molecular data with personalized treatments. PATIENTS AND METHODS: Since May 2020, the institutional MTB set at Fondazione IRCCS Istituto Nazionale Tumori of Milan met weekly via teleconference to discuss molecular data and potential therapeutic options for patients with advanced/metastatic solid tumors. RESULTS: Up to October 2021, among 1,996 patients evaluated, we identified >10,000 variants, 43.2% of which were functionally relevant (pathogenic or likely pathogenic). On the basis of functionally relevant variants, 711 patients (35.6%) were potentially eligible to targeted therapy according to European Society of Medical Oncology Scale for Clinical Actionability of Molecular Targets tiers, and 9.4% received a personalized treatment. Overall, larger NGS panels (containing >50 genes) significantly outperformed small panels (up to 50 genes) in detecting actionable gene targets across different tumor types. CONCLUSION: Our real-world data provide evidence that MTB is a valuable tool for matching NGS data with targeted treatments, eventually implementing precision oncology in clinical practice.Keywords
This publication has 17 references indexed in Scilit:
- Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach?PharmacoEconomics - Open, 2021
- Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community SettingJournal of Personalized Medicine, 2020
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working GroupAnnals of Oncology, 2020
- Small molecules, big impact: 20 years of targeted therapy in oncologyThe Lancet, 2020
- Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trialAnnals of Oncology, 2019
- Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French studyEuropean Journal of Human Genetics, 2018
- Relevance of a molecular tumour board (MTB) for patients’ enrolment in clinical trials: experience of the Institut CurieESMO Open, 2018
- Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor BoardJCO Precision Oncology, 2017
- Is the $1000 Genome as Near as We Think? A Cost Analysis of Next-Generation SequencingClinical Chemistry, 2016
- Molecular Tumor Board: The University of California San Diego Moores Cancer Center ExperienceThe Oncologist, 2014